When Kontoor Brands reports third-quarter results on Oct. 29, analysts at UBS expect the company to deliver a modest "beat and raise" — meaning earnings and revenue that come in slightly above Wall Street's forecasts, along with a small bump to full-year guidance. But the firm cautions that such a result may not be enough to change the minds of skeptical investors, many of whom are betting against the stock.
Kontoor, the apparel company behind denim brands Wrangler and Lee, as well as the recently acquired Helly Hansen, has seen its shares under pressure as investors question the growth trajectory. UBS's "channel checks" — a research method that tracks signals like web traffic, retail footfall, and inventory levels — point to solid demand for Wrangler and Helly Hansen during the quarter. That could translate into numbers that top expectations and a slightly higher outlook for the rest of the year.
Yet the problem, as UBS sees it, is that a small beat may already be priced in. When the market expects good news, the reaction can be muted. The bigger issue is Helly Hansen's growth in the US, which UBS believes won't show convincing signs of acceleration until fiscal 2027, even though the company has set a goal of 10% average annual sales growth over five years.
Why the market is skeptical
Kontoor's acquisition of Helly Hansen, a Norwegian outdoor apparel brand, was meant to diversify its portfolio beyond denim and tap into the growing outdoor and workwear markets. But integrating a new brand and proving its potential takes time. Investors, however, are often impatient. They want to see evidence that the deal will pay off sooner rather than later.
The gap between what investors want now and what management can prove soon helps explain why sentiment can look bearish even when analysts maintain positive ratings. Heavy short-selling — when investors borrow shares and sell them, hoping to buy them back at a lower price — suggests that many market participants are betting against the stock. This bearish positioning can create a situation where even good news doesn't lift the share price much, because the expectations are already low.
UBS's note highlights that the market is waiting for clearer evidence that Helly Hansen's US expansion is on track. The brand has strong recognition in Europe and other international markets, but its US presence is still developing. Management has set an ambitious target of 10% average annual sales growth over five years, but achieving that will require significant traction in the US market.
What it means for investors
For investors, the Oct. 29 earnings report is likely to be less about the quarterly numbers and more about the commentary around Helly Hansen's US milestones. If management can point to specific progress — such as new retail partnerships, increased shelf space, or strong early sales data — that could reassure the market. But if the timeline for meaningful acceleration remains pushed out to fiscal 2027, the stock may continue to trade at a discount.
Markets typically apply a heavier discount to cash flows expected further in the future. When a key growth driver is seen as a long way off, investors often assign a "show-me" valuation multiple — a lower price relative to earnings — until there's visible progress. That's why the stock's reaction may hinge less on a modest beat-and-raise and more on what management says about Helly's US expansion, timing, and early traction.
For everyday investors, this means that even if Kontoor beats expectations, the stock might not rally if the market views the beat as a one-off or if the Helly Hansen story remains unclear. It's a reminder that stock prices often reflect expectations, not just results. A company can report good numbers and still see its shares fall if investors were hoping for more.
Kontoor's situation is not unique. Many companies face similar dynamics when they make a big acquisition or try to enter a new market. The market rewards visible progress, not just promises. Until Kontoor can show that Helly Hansen is gaining real traction in the US, the skepticism is likely to persist.
In the meantime, investors will be watching the Oct. 29 report closely for any hints about the pace of Helly Hansen's growth. UBS's note suggests that the most convincing evidence may not arrive until fiscal 2027, but any positive surprises in the near term could help shift sentiment. For now, the market seems to be taking a wait-and-see approach.
